Tianeptine sodium API Manufacturers & Suppliers

Tianeptine sodium is used as an atypical antidepressant for major depressive disorder and anxiety in regions where it is approved. It has also been investigated for irritable bowel syndrome and studied for fibromyalgia‑related pain.

Tianeptine sodium belongs to the following therapeutic categories: Agents Causing Muscle Toxicity, Agents that produce hypertension, Agents that reduce seizure threshold, Analgesics, Antidepressive Agents. This positioning helps teams compare alternative APIs, anticipate pharmacology expectations, and align early research priorities.

The primary indications for Tianeptine sodium: Used primarily in the treatment of major depressive disorder and anxiety, It is currently being studied for fibromyalgia pain treatment. These use cases frame the target patient populations and help prioritize formulation and safety evaluations.

Recent studies suggest that Tianeptine sodium acts as a full agonist at the mu-type opioid receptor (MOR) , . The mu opioid receptors are currently being studied as effective targets for antidepressant therapies . It is believed that the clinical effects of Tianeptine sodium are owed to its modulation of these receptors . In addition to its actions on the opioid receptor, previous studies have owed its action to its effect on the serotonin receptor , , dopamine (D2/3) receptors , and glutamate receptors , , as discussed below: Tianeptine sodium has challenged the monoaminergic hypothesis of depression, as well as the widely supported monoaminergic mechanisms whereby the action of most known antidepressants have been explained . Specifically, this drug is thought to persistently alter glutamate receptor bursting of the hippocampal CA3 commissural associational synapse . Current research suggests that Tianeptine sodium produces its antidepressant effects through the modulation of glutamate receptor activity (for example, AMPA receptors and NMDA receptors) and affect the release of brain-derived neurotrophic factor (BDNF), which impacts neural plasticity . More recent studies by support the role of Tianeptine sodium in the modulation of glutaminergic activity in the amygdala, the emotional region of the brain associated with memories . Tianeptine sodium reduces the hypothalamic-pituitary-adrenal response to stress, and thus prevents stress-related behavioral issues . In rodents, the stress of acute restraint increases extracellular levels of glutamate in the basolateral amygdala an effect that was inhibited by Tianeptine sodium . Interestingly, the SSRI fluoxetine increased extracellular glutamate levels in the basolateral amygdala regardless of stress conditions. These data demonstrate that the mechanism of action of Tianeptine sodium is distinct from SSRIs and support the hypothesis that the mechanism of action of Tianeptine sodium relates to alteration of glutaminergic activity in the amygdala and the hippocampus . In addition to the above mechanisms, Tianeptine sodium is a unique antidepressant and anxiolytic medication that stimulates the uptake of serotonin (5-hydroxytryptamine; 5-HT), and 5-hydroxyindoleacetic acid (5-HIAA) in brain tissue . Although the monoaminergic neurotransmitters serotonin (5-HT), noradrenaline (NA) and dopamine (DA) are proven to be related to the occurrence of depressive disorders, it is now recognized that monoamine deficits are not sufficient to explain the mechanism of action of antidepressant medications .

Tianeptine sodium’s safety profile is defined by its full mu‑opioid receptor agonism, which can produce CNS and cardiorespiratory depression at high concentrations and has been implicated in fatal overdose cases. Excess exposure may also lead to cardiotoxic effects, reduced seizure threshold, and potential neurotoxicity. As a CYP3A substrate with a narrow therapeutic index, it requires attention to concentration‑related adverse effects and interactions, including the risk of serotonin syndrome when combined with serotonergic agents. Its opioid‑receptor activity also underscores documented concerns regarding misuse and dependence in inadequately monitored settings.

Tianeptine sodium’s low aqueous solubility supports use of solubility‑enhancing excipients or coated tablet designs to achieve reliable dissolution and absorption. Its moderate lipophilicity allows conventional oral solid forms without specialized lipid systems. The API should be handled to maintain purity and consistent release characteristics, with attention to factors that could alter dissolution performance. Because exposure may be influenced by CYP3A4‑modulating substances, potential interactions should be considered during formulation and clinical‑use planning.

Tianeptine sodium is classified as a small molecule. That classification shapes process design, impurity profiling, and analytical control strategies.

Oral Tianeptine sodium has low aqueous solubility, so maintaining consistent dissolution is a primary stability concern. Formulations often use solubility‑enhancing excipients or protective tablet coatings to support uniform drug release during shelf life. No additional stability issues are indicated in the provided information.